Table I.
Genotype frequencies of IL-1RN VNTR in all 515 study subjects and comparison of 133 patients with melanoma with 382 healthy controls.
| IL-1RN VNTR genotype/allele | All subjects (n=515) (%) | All patients with melanoma (n=133) (%) | Healthy controls (n=382) (%) | OR (95% CI) | P-value Melanoma vs. Control |
|---|---|---|---|---|---|
| 1/1 | 282 (54.8) | 61 (45.9) | 221 (57.9) | 0.62 (0.41–0.92) | 0.017 |
| 1/2 | 171 (33.2) | 58 (43.6) | 113 (29.6) | 1.84 (1.22–2.77) | 0.003 |
| 1/3 | 18 (3.5) | 5 (3.8) | 13 (3.4) | 1.11 (0.39–3.17) | 0.789 |
| 2/2 | 35 (6.8) | 5 (3.8) | 30 (7.9) | 0.46 (0.17–1.21) | 0.106 |
| 2/3 | 6 (1.2) | 2 (1.5) | 4 (1.0) | 1.44 (0.26–7.97) | 0.651 |
| 2/L (1/2 and 2/3)a | 177 (34.4) | 60 (45.1) | 117 (30.6) | 1.66 (1.24–2.79) | 0.002 |
| 1/2 and 2/2 and 2/3 and 2/4 | 212 (41.2) | 65 (48.9) | 147 (38.5) | 1.53 (1.03–2.27) | 0.036 |
| 1/3 and 2/3 and 3/3b | 25 (4.9) | 7 (5.3) | 18 (4.7) | 1.12 (0.46–2.75) | 0.799 |
| Allele 1 | 755 (73.3)c | 187 (70.3)c | 568 (74.3) | 0.82 (0.60–1.11) | 0.199 |
| Allele 2 | 247 (24.0) | 70 (26.3) | 177 (23.2) | 1.18 (0.86–1.63) | 0.300 |
| Allele 3 | 26 (2.5)d | 7 (2.6) | 19 (2.5)d | 1.06 (0.44–2.55) | 0.897 |
a
Heterozygous subjects containing the short allele 2 and one long allele (1, 3, 4 and 5) are denoted as 2/L according the literature (33).
b
Homozygous genotype 3/3 was present in only one healthy subject.
c
One metastatic patients had genotype 1/4, and one non-metastatic patient had genotype 1/5.
d
One healthy subject had genotype 3/3. IL-1RN, interleukin-1 receptor antagonist gene; OR, odds ratio; VNTR, variable number tandem repeat.